Though some cancer patients lack sufficient enzymes to metabolize capecitabine or 5-FU, many patients are not warned about the risks associated with these treatments.

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.

The Trump administration is changing the emergency abortion guidance currently in place at the nation's hospitals.

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

The US Food and Drug Administration (FDA) has expanded the approved use of Nubeqa (darolutamide) for patients with metastatic castration-sensitive prostate cancer (mCSPC). The drug is now approved for ...

Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.

Cancer organizations are urging researchers, oncologists, and other stakeholders to advocate for cancer research.

Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.

(HealthDay News) — Acupuncture may reduce nocturia in patients treated for prostate cancer, according to a research letter published in JAMA Oncology.

Sacituzumab tirumotecan demonstrated activity in a phase 2 trial of patients with advanced TNBC who had received no prior treatment in the advanced setting.

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...